ArticleRespiratory research2019
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Article in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review.European radiology · 2023Pooled it
- Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.American journal of respiratory and critical care medicine · 2026Trial
- Nationwide Incidence and Prevalence of Idiopathic Pulmonary Fibrosis in South Korea.Tuberculosis and respiratory diseases · 2026Article
- Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026Review
- Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Protective effects of PRELP protein in a mouse model of pulmonary fibrosis.Respiratory research · 2026Article
- Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Efficacy of pirfenidone in fibrotic hypersensitivity pneumonitis: a systematic review and meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2025Article
- Evaluating the robustness of deep learning models trained to diagnose idiopathic pulmonary fibrosis using a retrospective study.Medical physics · 2025Article
- Article
- THE EFFECT OF ARTESUNATE ON BLEOMYCIN-INDUCED PULMONARY FIBROSIS.Acta clinica Croatica · 2025Article
- Tension-induced organelle stress: an emerging target in fibrosis.Trends in pharmacological sciences · 2025Review
- Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases.Biomedicines · 2024Review
- Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.Respiratory research · 2024Article
- Mortality surrogates in combined pulmonary fibrosis and emphysema.The European respiratory journal · 2024Article
- Article
- Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.Respirology (Carlton, Vic.) · 2024Article
- Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.Frontiers in medicine · 2024Review
- Safety, effectiveness, and usefulness of higher-dose tablets of generic pirfenidone in patients with IPF: a nationwide observational study in South Korea.Frontiers in pharmacology · 2024Article
- Dual Drug-Loaded Coaxial Nanofiber Dressings for the Treatment of Diabetic Foot Ulcer.International journal of nanomedicine · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 9 institutions in 1 country.
Funding
Abstract
introductionPirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung function and overall survival (OS) in real-world cohorts on longer follow-up exists. PATIENTS/
methodsOf the enrolled Czech IPF patients (n = 841) from an EMPIRE registry, 383 (45.5%) received pirfenidone, 218 (25.9%) no-antifibrotic treatment and 240 (28.5%) were excluded (missing data, nintedanib treatment). The 2- and 5-yrs OS and forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DL
resultsDuring a 2-yr follow-up, less than a quarter of the patients progressed on pirfenidone as assessed by the decline of ≥10% FVC (17.0%) and ≥ 15% DL
conclusionOur study observed the 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient's IPF cohort. DL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.